Wednesday, 14 September 2016

Anti-tumour vaccine research (CDC assay) utilises DRAQ7

French scientists have shown use of a tetanus toxoid (TT) peptide sequence with a tumour multi-antigenic glycopeptide (MAG) where the TT sequence acts on T cells to further boost the anti-tumour response.

The work included a complement mediated cytotoxicity (CDC) assay.  The CDC assay was run in real-time (2h) using the far-red viability probe DRAQ7 (at 2 uM) to monitor cell death on the Essen Biosciences Incucyte Zoom.

This work was a collaboration between scientists affiliated with Inst. Pasteur, Inst. Curie, CNRS, INSERM and GSK Vaccines.

Laubreton, D., Bay, S., Sedlik, C. et al. Cancer Immunol Immunother (2016) 65: 315. doi:10.1007/s00262-016-1802-0

Quick link to article page

No comments :

Post a Comment